Reading TFX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TFX free→Reading TFX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TFX free→NYSEHealth CareMedical Instruments & SuppliesSnapshot 2026-06-12
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, but management's recent track record has been unsteady, with frequent disruptive corporate changes. The company was unprofitable over the past year, so its earnings quality can't be assessed. Peer multiples imply a price about 20% above where it trades (it looks cheap on this basis); the read is fair, but weakening, as it is priced roughly in line with peers, but recent financials or earnings quality are weakening. If TFX cuts guidance on the next call, that could be a meaningful negative. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 5 valuation methods, at three horizons. Current price $130.48. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $130 TFX trades at 12× p/e, below its 23× p/e peer median. Our $163 fair value sits above the price; medium confidence. Analysts: $128–$160. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price sits about 20% below a flat-multiple fair value; not enough history to forecast a comparison. This describes what's priced in, not a forecast of the move.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted -1.18x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $1.29 → $1.27 (-1.5% / 30d). 4 raised, 6 cut, 11 covering analysts.
1 upgrade, 0 downgrades / 30d, 0 maintained. 33% of analysts rate Buy.
1 PT revisions / 30d. Avg target 23.2% above current price.
0 positive, 1 negative / 30d. See F4 management tile for the event list.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$151.
How much price usually moves either way.
On a bad day, this stock has moved -$300.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $2,435.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-12
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Earnings results will show if revenue growth is improving after the recent miss.
Confirms one read:Q2 earnings report shows revenue growth above 5% year over year.
Confirms the other:Q2 earnings report shows revenue growth below 0% year over year.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for TFX yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 8, 2026, the independent members of the Board of Directors (the “Board”) of Teleflex Incorporated (the “Company”), upon recommendation by the Compensation Committee of the Board, approved a special restricted stock unit award with a grant date fair value of $600,000 to Stuart A. Randle. The award is intended to recognize Mr. Randle’s signif…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$128.00 – $160.00 (median $148.50) · 6 analysts · as of 2026-06-08
Looks cheaper than most peers in the same business.
Cheaper than its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Equipment.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
TFX Teleflex | Above typical Show detailsSector percentile: 92 of 100 | fair | moderate |
ABT Abbott Laboratories | Above typical Show detailsSector percentile: 93 of 100 | inexpensive | moderate |
ISRG Intuitive Surgical | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
SYK Stryker Corporation | Typical Show detailsSector percentile: 67 of 100 | fair | moderate |
MDT Medtronic | Above typical Show detailsSector percentile: 89 of 100 | fair | moderate |
5 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
Not investment advice. As of 2026-06-12.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-12.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Complete the strategic divestitures in the second half of 2026 to optimize the portfolio.
Maintain full year 2026 revenue growth guidance of 14.40% to 15.40% on a GAAP basis.
Allocate majority of net proceeds from divestitures to share repurchase and reduce debt by $800 million.
Emphasize revenue growth through strategic initiatives and market expansion.
Continue to provide consistent dividend payments to shareholders.
Why it matters: The new CEO's strategy will shape future growth and operational focus.
Confirms:A public announcement shows a plan focused on growing revenue.
Disproves:No clear strategic direction is communicated by the new CEO.
Why it matters: Sector growth trends affect Teleflex's revenue and performance.
Confirms:Healthcare revenue growth remains above 10% year over year.
Disproves:Healthcare revenue growth drops below 5% year over year.
Why it matters: Keeping the dividend shows strong capital use and care for shareholders.
Confirms:Dividend remains at $0.34 per share for the next quarter.
Disproves:Dividend is cut or not maintained at $0.34 per share.
Why it matters: The new CEO's plan will affect growth and operations.
Confirms one read:New CEO outlines a clear growth strategy in a press release.
Confirms the other:No clear plan is shared after the change.
Entry into a Material Definitive Agreement. On May 26, 2026, Teleflex Incorporated (the “Company”) and certain of its subsidiaries entered into a new Credit Agreement (as amended, restated, supplemented or otherwise modified, refinanced or replaced from time to time, the “Company Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A., PNC Bank, National Association, HSBC Securities (USA) Inc., Wells Fargo Bank, National Association and Sumitomo Mitsu…
Other Events. On June 1, 2026, Teleflex Incorporated (the “Company”) announced that it priced its private offering of $500.0 million aggregate principal amount of its 5.875% Senior Notes due 2032 (the “Notes”). The Company intends to use the net proceeds from the offering, together with cash on hand, to redeem all of its outstanding 4.625% Senior Notes due 2027 (the “2027 Notes”). A copy of the press release announcing the pricing of the offering is attached hereto as Exhibit 99.1 and is inco…
Other Events. On June 1, 2026, the Company announced that it intends to offer $500.0 million aggregate principal amount of Senior Notes due 2032 (the “Notes”). The Company intends to use the net proceeds from the offering, together with cash on hand, to redeem all of its outstanding 4.625% Senior Notes due 2027 (the “2027 Notes”). A copy of the press release announcing the offering is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The offering of the Notes will be ma…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in